GH Research PLC
GHRS
Company Profile
Business description
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
Contact
Dawson Street
Joshua Dawson House
Dublin 2D02 RY95
IRLT: +353 14378334
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
73
Stocks News & Analysis
stocks
Avoid these overvalued ASX shares
The two shares with the highest price to fair value in our Australian coverage.
stocks
Going into earnings, is Microsoft stock a buy, a sell, or fairly valued?
Watching AI monetization, capex’s impact on margins, and guidance on Azure.
stocks
Lithium’s latest drop and what it means for ASX investors
Volatility returns to the lithium market.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,004.90 | 14.70 | 0.16% |
| CAC 40 | 8,437.89 | 74.75 | 0.89% |
| DAX 40 | 25,155.41 | 144.06 | 0.58% |
| Dow JONES (US) | 52,218.58 | 6.06 | -0.01% |
| FTSE 100 | 10,716.97 | 131.06 | 1.24% |
| HKSE | 24,892.66 | 239.63 | -0.95% |
| NASDAQ | 25,690.90 | 146.30 | -0.57% |
| Nikkei 225 | 66,115.60 | 116.59 | -0.18% |
| NZX 50 Index | 13,763.18 | 107.15 | 0.78% |
| S&P 500 | 7,498.96 | 10.24 | -0.14% |
| S&P/ASX 200 | 8,823.00 | 16.50 | 0.19% |
| SSE Composite Index | 3,867.03 | 2.67 | 0.07% |